Compounds, compositions, and methods for modulating cftr

A compound represented by Formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• X1 is selected from the group consisting of —Si(R3)3, —C(CY3)3, hydrogen, halogen, C1-3alkyl optionally substituted by one or more halogens, C3-6cycloalkyl, and 4-6 membered saturated monocyclic heterocyclyl;
• wherein C3-6cycloalkyl and 4-6 membered saturated monocyclic heterocyclyl may be optionally be substituted by one, two, three or more substituents each independently selected for each occurrence from R11;
• X2 is selected from the group consisting of —Si(R3)3 and —C(CY3)3;
• wherein at least one of X1 or X2 is —Si(R3)3;
• R3 is independently selected for each occurrence from the group consisting of hydroxyl, C1-4alkyl, C1-4alkoxy, and phenyl, wherein C1-4alkyl, C1-4alkoxy, and phenyl may optionally be substituted by one, two, three or more deuterium atoms;
• or two R3 groups together with the silicon to which they are attached form a 4-6 membered saturated cyclosilane;
• Y is independently selected for each occurrence from the group consisting of hydrogen and deuterium;
• and
• R11 is independently selected for each occurrence from the group consisting of hydrogen, halogen, hydroxyl, cyano, and C1-6alkyl;
• wherein C1-6alkyl may be optionally substituted by one or more substituents each independently selected for each occurrence from the group consisting of halogen, hydroxyl, and C1-6alkoxy.